Moss, 31 January 2022

Reference to the stock exchange release dated 5 October 2021 and the 3rd quarter
report released on 21 October 2021, Gentian Diagnostics ASA, a fast-growing
developer and manufacturer of innovative and efficient diagnostics for better
treatment decisions, has entered a global distribution contract for the Gentian
Calprotectin Immunoassay GCAL® with Siemens Healthineers. The GCAL® assay will
be offered on the Siemens Healthineers BNTM II, BN ProSpec®, and Atellica® NEPH
platforms and positioned toward the rheumatoid arthritis market, with launch
scheduled for the first half of 2022. Siemens Healthineers is a market leader in
nephelometric plasma protein testing.

The GCAL® assay is available for quantitative measurement of calprotectin in
plasma and serum, which is an early biomarker for detection and assessment of
the inflammatory response to severe infections and other inflammatory conditions
like rheumatoid arthritis. The Siemens Healthineers BN II platform is a fully
automated system with a large installed base, and additional systems from
Siemens Healthineers are scheduled to be added at a later stage.

"This is an important milestone for Gentian, as this makes our innovative GCAL®
assay readily available for a larger patient group. Siemens Healthineers is one
of the global leaders in clinical diagnostics, with its large installed base of
laboratory testing systems and assays," says Gentian Diagnostics CEO Hilja
Ibert. 

The GCAL® assay will initially be made available in Europe, with expansion to
additional countries or regions depending on regulatory clearance.

Rheumatoid arthritis is a chronic inflammatory autoimmune disease affecting more
than 1% of the adult world population, and early detection is critical to ensure
prevention of disabling joint erosion. Industry analysts estimate the value of
the rheumatoid arthritis diagnosis test market at more than USD 550 million in
2020, with growth potential to more than USD 750 million by 2027, and the
serviceable market for GCAL in this segment is estimated at USD 30-60 million.

Earlier in 2021, Gentian outlined the roadmap for its portfolio of high-impact
diagnostic tests, which supports the company's revenue growth ambitions. The
company expects GCAL® to be one of the main value drivers in the realization of
this growth roadmap, and confirming clinical relevance and entering global
commercial partnerships are key enablers.


For further information, please contact:
Hilja Ibert, CEO
hilja.ibert@gentian.no
+47 919 05 242 (mobile)

Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Njaal Kind, CFO at Gentian
Diagnostics ASA, on 31 January 2022 at 14:00 CET.